Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARO-ATXN1
- Development stage
- Preclinical
- Lead developer
- Arrowhead Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
ARO-ATXN1 is an investigational RNA interference (RNAi) therapeutic designed to silence the expression of the ATXN1 gene, which encodes ataxin 1 protein. Mutations in this gene are responsible for spinocerebellar ataxia type 1 (SCA1), a rare neurodegenerative disorder. The drug aims to reduce levels of toxic mutant ataxin 1 protein in the central nervous system, potentially slowing or halting disease progression[4][7]. Arrowhead Pharmaceuticals is developing ARO-ATXN1 as part of its collaboration with Sarepta Therapeutics.
02
Targets
ATXN1 mRNA (Ataxin-1 mutant transcript)
Beyond the preview
Go deeper on ARO-ATXN1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARO-ATXN1.